Source - LSE Regulatory
RNS Number : 7585J
Diaceutics PLC
09 April 2024
 

Diaceutics appoints Amie Mc Neice as VP of Marketing

 

Belfast and London, 9 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce the appointment of Amie Mc Neice as Vice President of Marketing. Amie previously held senior marketing and business development roles with Almac Group, Fibrus and Kingspan Plc.

 

Amie brings a wealth of marketing leadership experience to the team and will focus on delivering our 3-year marketing vision, brand positioning, messaging and integration of marketing automation. Amie has significant experience in working with US pharma customers.

 

Diaceutics is dedicated to scaling its sales and marketing capabilities in the US and Europe through 2024.

 

Diaceutics continues to invest in product development with the further expansion of its product management team in 2024. The product management team will deliver our product roadmap and co-ordinate our product activities across, data, scientific and medical services, engagement solutions, engineering and marketing.

 

Jillian Beggs, Chief Commercial Officer of Diaceutics, commented: "I am delighted to welcome Amie to the team at Diaceutics. Our continued investment in sales and marketing supports our mission to provide the data, technology solutions and insights that enable our pharma and biotech customers revolutionise the commercialisation of their products and ultimately improve patient outcomes."

 

Amie Mc Neice, VP Marketing of Diaceutics commented: "I have long admired Diaceutics and look forward to working with the team as we expand our sales and marketing capabilities and serve our customers' needs across the US and Europe."

 

 

Enquiries: 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer  

 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com



Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison, Nick Harland, Kate Hanshaw 




Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon, Kieran Breheny  

diaceutics@almastrategic.com



About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQKFBBFBKDPQK
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Diaceutics PLC (DXRX)

-4.00p (-3.88%)
delayed 15:57PM